Acute hepatitis due to olmesartan: an uncommon entity

Rev Esp Enferm Dig. 2021 Mar;113(3):223-224. doi: 10.17235/reed.2020.7236/2020.

Abstract

We report the case of a hypertensive 54-year-old female who had been under treatment with olmesartan (40 mg daily) for a month. She was referred due to hypertransaminasemia and also reported asthenia and a 7 kg weight loss.

Publication types

  • Case Reports

MeSH terms

  • Antihypertensive Agents / adverse effects
  • Blood Pressure
  • Female
  • Hepatitis* / drug therapy
  • Humans
  • Hypertension* / drug therapy
  • Imidazoles / adverse effects
  • Middle Aged
  • Tetrazoles / adverse effects

Substances

  • Antihypertensive Agents
  • Imidazoles
  • Tetrazoles
  • olmesartan